Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2019-03-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于2019年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a company regarding its expected related party transactions for the fiscal year 2019. It includes details about the nature of the transactions, the parties involved, pricing policies, independent directors' opinions, and supervisory board opinions. The document is relatively short (3653 characters) and structured as a public disclosure or announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It also does not fit categories like earnings release, management reports, or capital updates. The content aligns with a regulatory announcement about related party transactions, which is a common type of regulatory filing. Therefore, the best classification is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit other specific categories.
2019-03-20 Chinese
关于2019年度向银行申请综合授信额度并对子公司授信额度内贷款提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding its application for a comprehensive credit line from banks and the provision of guarantees for loans within the credit limits to its subsidiaries. It includes detailed information about the credit amounts, terms, guarantees, and financial data of the subsidiaries. The document is not a full financial report but rather a disclosure about financing activities and guarantees related to credit facilities. There is no indication that this is an annual or interim report, audit report, or earnings release. The content fits the category of updates on company fundraising, financing activities, or capital structure changes, which corresponds to Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive disclosure about financing.
2019-03-20 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes detailed evaluation and assurance of the company's internal control effectiveness related to financial reporting as of December 31, 2018. It references auditing standards and internal control evaluation guidelines, and it is issued by an accounting firm with certification dates in 2019. The content is focused on internal control assessment, including control environment, risk assessment, control activities, and internal supervision, with no financial statements or earnings data presented. This matches the description of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. The document length (12,563 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-03-20 Chinese
2018年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled "葵花药业集团股份有限公司2018年度内部控制自我评价报告" which translates to "Internal Control Self-Evaluation Report for 2018". It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2018. The content includes principles of internal control, evaluation scope, control environment, risk assessment, control activities, supervision, and defect recognition and rectification. It is a comprehensive internal control report, not an announcement or a brief summary. It does not fit into categories like Annual Report (10-K) or Audit Report (AR) since it focuses specifically on internal control self-evaluation rather than full financial statements or audit opinions. The document is not a certification or a short announcement, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Given the nature of the document, it best fits the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. Confidence is high due to the detailed and specific nature of the report and its length (over 10,000 characters). FY 2018
2019-03-20 Chinese
第三届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the seventh meeting of the third Supervisory Board of the company, dated March 20, 2019. It includes approvals of various reports related to the 2018 fiscal year, such as the Supervisory Board's work report, the full annual report and summary, the financial settlement report, profit distribution plan, internal control self-assessment report, and other related matters. The document repeatedly states that these reports and proposals will be submitted to the 2018 Annual General Meeting (AGM) for approval. The document itself does not contain the full annual report or detailed financial statements but rather the meeting resolutions approving these reports and plans. The length is 3554 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and approvals related to the annual report and other matters, but it is not the annual report itself nor a direct report publication announcement. It is not a Proxy Solicitation or Voting Results announcement, as it does not provide voting results from a shareholder meeting but from the Supervisory Board meeting. Hence, the most appropriate classification is Regulatory Filings (RNS).
2019-03-20 Chinese
关于召开2018年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2018 Annual General Meeting (AGM) of 葵花药业集团股份有限公司, including the meeting date, agenda items, voting procedures, and proxy forms. It does not contain the actual annual report or financial statements but rather the announcement and logistical details for the AGM. The document length is about 5,839 characters, which is consistent with a detailed meeting notice rather than a full annual report. The content focuses on the meeting notice and voting instructions, which aligns with the definition of AGM Information (AGM-R).
2019-03-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.